Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma

作者：Reinhard Dummer, Shahneen Sandhu, Wilson H. Miller, Marcus O. Butler, Matthew H. Taylor, L. M. Heinzerling, Christian U. Blank, Eva Muñoz‐Couselo, Howard A. Burris, Michael A. Postow, Bartosz Chmielowski, M R Middleton, C Berking, Jessica C. Hassel, Anja Gesierich, Cornelia Mauch, Joseph F. Kleha, A. Polli, Allison S. Harney, A. di Pietro, Paolo A. Ascierto · 发表于：Future Oncology · 年份：2026 · DOI：10.1080/14796694.2026.2643481 · 被引用次数：1 · 研究领域：Melanoma and MAPK Pathways、Cutaneous Melanoma Detection and Management、Lung Cancer Treatments and Mutations

Plain Language SummaryWhat is this summary about?This summary presents results from the LOGIC 2 study, which tested encorafenib and binimetinib plus a third drug (ribociclib, infigratinib, capmatinib, or buparlisib) for the treatment of advanced or metastatic BRAF V600-mutant melanoma. These drugs are part of a group of drugs known as a targeted therapy. Targeted therapies attack specific molecules involved in cancer cell growth, while minimizing damage to healthy cells.What are the key takeaways?The percentage of participants whose tumors shrank or were no longer detectable after treatment with encorafenib plus binimetinib was higher among participants who had not previously been treated with drugs blocking BRAF and/or MEK proteins compared with those who had. BRAF and MEK proteins can help cancer cells grow. Adding a third drug after people’s cancer worsened did not have a meaningful effect.What were the main conclusions reported by the researchers?The results confirm that people with BRAF V600-mutant melanoma benefit from treatment with encorafenib plus binimetinib.Clinical trial number: NCT02159066